Understanding patterns of pathologic response following neoadjuvant immunotherapy for solid tumors.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

1. Immune-related pathologic response (irPR) features and immunotherapeutic response score (ITRS) predict survival following neoadjuvant/conversion combined immunotherapy in intrahepatic cholangiocarcinoma.Virchows Archiv : an international journal of pathology · 2026
   Article
2. [Oncologic surgery in the context of immunotherapy, neoadjuvant treatment and HPV : Clinical, immunological and translational aspects].HNO · 2026
   Review
3. Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future.World journal of gastroenterology · 2023
   Review
4. A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.Medicina (Kaunas, Lithuania) · 2022
   Article
5. Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy.Frontiers in oncology · 2021
   Review
6. [Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020
   Review
7. Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.BioMed research international · 2020
   Review
8. The Combination of Stereotactic Body Radiation Therapy and Immunotherapy in Primary Liver Tumors.Journal of oncology · 2019
   Review

Corrections and comments

• Comment on
  Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).2018

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as